On July 8, 2025, analyst Vijay Kumar from Evercore ISI Group maintained an "Outperform" rating for Exact Sciences (EXAS, Financial). This decision reflects a continued positive outlook on the company's performance.
In addition to maintaining the rating, Evercore ISI Group has raised its price target for Exact Sciences (EXAS, Financial) from $66.00 to $68.00 USD. This adjustment represents a 3.03% increase in the price target, indicating confidence in the stock's potential for growth.
Exact Sciences (EXAS, Financial), a prominent player in the diagnostics industry, continues to be viewed favorably by analysts, as demonstrated by the updated price target. Investors may find this news significant as it highlights the analyst's expectation of upward momentum for the company's stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Exact Sciences Corp (EXAS, Financial) is $68.92 with a high estimate of $90.00 and a low estimate of $54.00. The average target implies an upside of 31.33% from the current price of $52.48. More detailed estimate data can be found on the Exact Sciences Corp (EXAS) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, Exact Sciences Corp's (EXAS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Exact Sciences Corp (EXAS, Financial) in one year is $78.00, suggesting a upside of 48.63% from the current price of $52.48. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Exact Sciences Corp (EXAS) Summary page.
